Maxim Group reiterated coverage of Cyclo Therapeutics with a rating of Buy and set a new price target of $25.00 from $12.00 previously
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio
– Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first physician in the U.S. to use cyclodextrins for treatment in NPC, compassionate use – Site activation ongoing and currently enrolling patients in pivotal Phase 3 study, TransportNPC™ – Data seen to-date provide support for the capacity of Trappsol® Cyclo™ to stabilize disease progression with home-based intravenous infusions in NPC and demonstrate acceptable safety profile of Trappsol® Cyclo™ administered intravenously for more than 2 years Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-cha
SC 13G/A - Cyclo Therapeutics, Inc. (0000922247) (Subject)
SC 13G/A - Cyclo Therapeutics, Inc. (0000922247) (Subject)
SC 13G - Cyclo Therapeutics, Inc. (0000922247) (Subject)
4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)
4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)
4 - Cyclo Therapeutics, Inc. (0000922247) (Issuer)
8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)
425 - Cyclo Therapeutics, Inc. (0000922247) (Subject)
8-K - Cyclo Therapeutics, Inc. (0000922247) (Filer)
https://register.epo.org/application?number=EP19805439
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Cyclo Therapeutics (NASDAQ:CYTH) with a Buy and maintains $3 price target.
TransportNPC™ is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for the treatment of Niemann-Pick Disease Type C1 (NPC1)Topline data from the 48-week interim analysis of 104 enrolled patients is anticipated for H1 2025
Two posters presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024 Pivotal TransportNPC™ study is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for NPC1 Topline data from the 48-week interim analysis of 104 enrolled patients in TransportNPC™ on track for H1 2025 Trappsol® Cyclo™ demonstrated to be well tolerated in ongoing substudy with a safety profile consistent with that of completed phases Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio